Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 91 Melanoma 74 Squamous Cell Carcinoma of Head and Neck 47 Neoplasms 44 Neoplasm Metastasis 43 Lung Neoplasms 37 Carcinoma, Renal Cell 36 Colorectal Neoplasms 35 Breast Neoplasms 34 Triple Negative Breast Neoplasms 30 Stomach Neoplasms 26 Carcinoma, Transitional Cell 26 Ovarian Neoplasms 25 Head and Neck Neoplasms 24 Parkinson Disease 4, Autosomal Dominant Lewy Body 21 Esophageal Neoplasms 20 Pancreatic Neoplasms 18 Uterine Cervical Neoplasms 17 Urinary Bladder Neoplasms 16 Endometrial Neoplasms 16 Small Cell Lung Carcinoma 15 Carcinoma, Hepatocellular 15 Sarcoma 13 Recurrence 12 Glioblastoma 12 Carcinoma 12 Prostatic Neoplasms 11 Lymphoma 11 Mesothelioma 9 Carcinoma, Merkel Cell 9

Interventions

pembrolizumab 1 liposomal doxorubicin 1 fludarabine phosphate 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Adenoviridae Infections × pembrolizumab × Clear all

NCT05271318 2026-05-05

PROTA

TILT Biotherapeutics Ltd.

Phase 1/2 Active not recruiting

Adenoviridae Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡